PIPRA, University of California, Davis, CA 95616, USA.
Vaccine. 2011 May 31;29(24):4086-93. doi: 10.1016/j.vaccine.2011.03.052. Epub 2011 Apr 13.
Global access to advanced vaccine technologies is challenged by the interrelated components of intellectual property (IP) management strategies, technology transfer (legal and technical) capabilities and the capacity necessary for accelerating R&D, commercialization and delivery of vaccines. Due to a negative association with the management of IP, patents are often overlooked as a vast resource of freely available, information akin to scientific journals as well as business and technological information and trends fundamental for formulating policies and IP management strategies. Therefore, a fundamental step towards facilitating global vaccine access will be the assembly, organization and analysis of patent landscapes, to identify the amount of patenting, ownership (assignees) and fields of technology covered. This is critical for making informed decisions (e.g., identifying licensees, building research and product development collaborations, and ascertaining freedom to operate). Such information is of particular interest to the HIV vaccine community where the HIV Vaccine Enterprise, have voiced concern that IP rights (particularly patents and trade secrets) may prevent data and materials sharing, delaying progress in research and development of a HIV vaccine. We have compiled and analyzed a representative HIV vaccine patent landscape for a prime-boost, DNA/adenoviral vaccine platform, as an example for identifying obstacles, maximizing opportunities and making informed IP management strategy decisions towards the development and deployment of an efficacious HIV vaccine.
全球获取先进疫苗技术面临着知识产权（IP）管理策略、技术转让（法律和技术）能力以及加速疫苗研发、商业化和交付所需的能力等相互关联的组成部分的挑战。由于与知识产权管理的负面关联，专利往往被忽视，它们是一个巨大的资源，提供了类似于科学期刊的免费信息，以及商业和技术信息和趋势，这些对于制定政策和知识产权管理策略至关重要。因此，促进全球疫苗获取的一个基本步骤将是组装、组织和分析专利格局，以确定专利数量、所有权（受让人）和所涵盖的技术领域。这对于做出明智的决策（例如，确定被许可方、建立研究和产品开发合作关系以及确定运营自由）至关重要。这种信息对于 HIV 疫苗界特别感兴趣，因为 HIV 疫苗企业已经表示担心，知识产权（特别是专利和商业秘密）可能会阻止数据和材料共享，从而延迟 HIV 疫苗的研发进展。我们已经编制和分析了一个代表性的 HIV 疫苗专利格局，以 DNA/腺病毒疫苗平台为例，旨在确定障碍、最大化机会并就有效 HIV 疫苗的开发和部署做出明智的知识产权管理策略决策。
